Anti-viral efefcts of a Novel RSV polymerase inhibitor, PC786, on primary airrway epithelial cells.
What is it about?
Effective anti‐respiratory syncytial virus (RSV) agents are still not available for clinical use. We have investigated the effects of late therapeutic intervention (clinical treatment senario) with a novel inhaled RSV polymerase inhibitor, PC786, on RSV infection in human airway epithelium. Late therapeutic intervention with the RSV polymerase inhibitor, PC786, reduced the viral burden quickly in human airway epithelium. Thus, PC786 demonstrates the potential to be an effective therapeutic agent to treat active RSV infection.
Why is it important?
Effective anti‐respiratory syncytial virus (RSV) agents are still not available for clinical use and major recent approch is virus entry inhibition for prophylactic use. This new approach with polymerase inhibitor enables to inhibit RSV replication even after virus inbfection is established. In addition, this molecule is optimised for inhalation, leading limited systemic efefcts and high local exposure for more potent anti-viral effect and less mutation induction.
The following have contributed to this page: Dr Kazuhiro Ito
In partnership with: